Archives
-
Verapamil Targets Txnip in Osteoporosis
2026-10-01
A 2025 Journal of Orthopaedic Translation study identifies Txnip as a mechanistic link between verapamil exposure and abnormal bone remodeling. Human genetic data, cell assays, transcriptomics, and an ovariectomy mouse model together suggest that verapamil can reduce bone loss through ChREBP–Txnip signaling in osteoclasts and osteoblasts, while important translational limitations remain.
-
Metformin Hydrochloride in Whole-Blood Assays
2026-10-01
Use Metformin Hydrochloride as a tunable metabolic intervention rather than a single-purpose glucose reagent. This guide connects AMPK-centered mechanism studies with standardized whole-blood cytokine assays, emphasizing formulation, donor controls, timing, and interpretation.
-
Naloxone hydrochloride in Opioid Research
2026-09-30
Learn how to deploy naloxone hydrochloride as a controlled opioid-receptor perturbation tool across behavioral, cellular, and immune assays. This guide connects withdrawal-anxiety research with practical stock preparation, assay controls, troubleshooting, and translational interpretation.
-
MOG (35-55) Peptide: EAE Assay Reliability
2026-09-29
This scenario-driven guide explains how MOG (35-55) Peptide, SKU A8306, can support controlled EAE induction and complementary neuroinflammation or cell-viability workflows. It covers formulation, dosing, assay controls, interpretation limits, and practical criteria for selecting a reliable myelin oligodendrocyte glycoprotein peptide.
-
Mc-Val-Cit-PABC-PNP Workflow Guide
2026-09-29
Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for antibody-drug conjugate workflows that require enzyme-responsive payload release in lysosomal environments. It is intended for controlled scientific research, with strong DMSO solubility but poor suitability for water- or ethanol-based handling, diagnostic use, or therapeutic administration.
-
CTCF Maintains Centromere Function in Mitosis
2026-09-28
The reference study uses rapid, inducible CTCF degradation to show that CTCF preserves centromere organization, metaphase plate geometry, mitotic fidelity, and post-mitotic nuclear shape. Its results distinguish CTCF loss from simple failure to recruit CENP-E and instead support a centromere-maintenance model related to chromosome tension and cohesin-associated architecture.
-
PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance
2026-09-28
Dong and colleagues developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery, aiming to restore PTEN expression and suppress PI3K/Akt signaling in trastuzumab-resistant breast cancer. The study links pH-triggered carrier changes to tumor-cell uptake and improved antitumor activity in experimental models, while leaving clinical efficacy and broader transferability to be established.
-
Dasatinib: A Probe of Kinase Causality
2026-09-27
Dasatinib (BMS-354825) is a potent Src and Bcr-Abl inhibitor, but its value in cancer research depends on asking what its perturbation can—and cannot—establish. This article connects kinase-focused experiments with recent thymic epithelial tumor findings and outlines a cautious framework for testing pathway relationships.
-
Affordable GRO-seq for Bread Wheat Nascent RNA
2026-09-26
Chen and colleagues describe a bread-wheat GRO-seq workflow that adds ribosomal RNA depletion after nuclear RNA isolation and before nascent-RNA immunoprecipitation. In their application to enhancer transcription in allohexaploid wheat, the protocol increased the reported proportion of valid sequencing data 20-fold, offering a practical way to use sequencing capacity more efficiently in complex genomes.
-
SP600125 and the Translational Logic of JNK
2026-09-25
A mechanistic and experimental framework for using SP600125 to test JNK’s contribution to infection-linked inflammatory signaling, while distinguishing pathway evidence from translational hypotheses.
-
Protease Inhibitor Cocktail for DFCP1–ATGL Studies
2026-09-25
Protect DFCP1, ATGL, and other lipid-droplet proteins during extraction without confusing post-lysis preservation with the biology of starvation-driven lipolysis. This practical guide covers lysate preparation, complex analysis, EDTA-sensitive assays, and troubleshooting with a ready-to-use 100X aqueous inhibitor concentrate.
-
SB 431542 for Reliable TGF-β Assays
2026-09-24
A scenario-driven guide to using SB 431542 (SKU A8249) to investigate ALK5-dependent signaling, proliferation, and assay interpretation. It combines product data with practical controls and clearly distinguishes pathway evidence from experiments that have not tested the compound.
-
Budesonide Workflows for Lung Permeability Research
2026-09-24
Use Budesonide to connect airway inflammation assays with biomimetic lung-permeability screening—while keeping those readouts distinct. This workflow translates recent IAM-LC and OT-CEC findings into practical compound handling, assay selection, and troubleshooting guidance for respiratory disease research.
-
TAK-242 (Resatorvid) for Reliable Cell Assays
2026-09-24
Practical guidance for using TAK-242 (Resatorvid), SKU A3850, to investigate LPS-triggered TLR4 signaling without mistaking inflammatory changes for cell loss. Covers assay controls, solvent handling, interpretation, and the context-dependent limits of pathway inhibition.
-
Sumatriptan as an Anti-Inflammatory Agent
2026-09-23
This systematic review evaluates evidence that sumatriptan, beyond its established migraine and cluster-headache indications, can modulate inflammatory signaling through 5-HT1B/1D receptors, nitric oxide pathways, CGRP release, and cytokine-associated mechanisms. Its findings support pharmacological repositioning as a research hypothesis, while the heterogeneous preclinical evidence requires careful separation of mechanistic plausibility from clinical efficacy.